Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1617 • 2016 ACR/ARHP Annual Meeting
Treatment with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, Improves Fatigue and Health-Related Physical and Emotional Well Being in Patients with Active Rheumatoid Arthritis Refractory to Conventional or Biologic Therapy: Results of 2 Global, Placebo-Controlled, Phase 3 Trials
Clifton Bingham III¹, Yoshiya Tanaka², George Karpouzas³, Tsutomu Takeuchi⁴, Daniel Aletaha⁵, Carter Thorne⁶, Shihong Sheng⁷, Weichun Xu⁷, Ravi Rao⁸, Kaiyin Fei⁷, Benjamin Hsu⁷, Prasheen Agarwal⁷, Sharon Popik⁷, Regina Kurrasch⁹, Steve Peterson⁷, Rita Ganguly⁹, Chenglong Han⁷ and Kelly McQuarrie⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁴Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁵Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁶University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, ⁹GlaxoSmithKline, Collegeville, PA
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience both substantial fatigue and a decline in their health-related physical and emotional well-being. Sirukumab is a…
Abstract Number: 1651 • 2016 ACR/ARHP Annual Meeting
A Case Series on Patients on Tofacitinib in Combination with a Biologic
Nashla Barroso¹ and Daniel E. Furst², ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Although there have been significant advances in the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). patients can experience a lack of or…
Abstract Number: 140 • 2016 ACR/ARHP Annual Meeting
Relationship Between the Prevalence of Subclinical Tenosynovitis and Therapy in Patients with RA in Clinical Remission: Results from Italian Society of Rheumatology Study Group
Simone Parisi¹, Greta Carrara², Carlo Alberto Scirè^3,4, Alberto Batticciotto⁵, Emanuela Bellis⁶, Marco Canzoni⁷, Orazio De Lucia⁸, Ilaria Farina⁹, Carlo Venditti¹⁰, Annamaria Iagnocco^11,12 and Georgios Filippou¹³, ¹Department of Rheumatology, University Hospital Città Della Salute e della Scienza di Torino, Turin, Italy, ²Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, ³Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, ⁴Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, ⁵Rheumatology, L. Sacco University Hospital, Milano, Italy, ⁶Rheumatology, Ospedale Mauriziano, Turin, Italy, ⁷A.O. Sant'Andrea, Rome, Italy, ⁸Rheumatology, Orthopedic Institute Gaetano Pini, Milano, Italy, ⁹Rheumatology Unit AOU S.Anna, Ferrara, Italy, ¹⁰A.O. Rummo, Benevento, Italy, ¹¹Sapienza University of Rome, Rome, Italy, ¹²Sapienza University of Rome, Italy, Roma, Italy, ¹³University of Siena, Siena, Italy
Background/Purpose: This study is a sub-analysis of the data from the patient cohort of STARTER (The Sonographic Tenosynovitis Assessment in RheumaToid arthritis patiEnts in Remission)…
Abstract Number: 2174 • 2016 ACR/ARHP Annual Meeting
Effect of Anti-Rheumatic Treatment on Selenium Levels in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gia Deyab¹, Ingrid Hokstad², Milada Cvancarova Småstuen³, Stefan Agewall⁴, Jon Elling Whist⁵ and Ivana Hollan^5,6,7,8, ¹Department of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway, ²Lillehammer Hospitat for Rheumatic Diseases, Lillehammer, Norway, ³Institution of health care - Health science PhD program, Oslo and Akershus University College, Oslo, Norway, ⁴University of Oslo, Oslo, Norway, ⁵Innlandet Hospital Trust, Lillehammer, Norway, ⁶Brigham and Women’s Hospital, Boston, MA, ⁷Harvard Medical School, Boston, MA, ⁸Lillehammer Hospital for Rheumatic Diseases, Lillahammer, Norway
Background/Purpose: The cause of the increased cardiovascular risk in inflammatory rheumatic diseases (IRDs) is still unclear. Intriguingly, selenium-deficiency, which might be caused by poor diet or…
Abstract Number: 179 • 2016 ACR/ARHP Annual Meeting
CD11b+Gr1dimcells, Which Are Induced By GM-CSF Produced By Th17 and Group3 Innate Lymphoid Cell, May Facilitate the Progression of Pneumonitis in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Takaichi Okano², Soshi Takahashi³ and Akio Morinobu¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Rheumatoid lung disease is a prognostic factors of rheumatoid arthritis in human. The pathogenesis and the mechanism of rheumatoid lung disease is unclear. Zymosan…
Abstract Number: 2558 • 2016 ACR/ARHP Annual Meeting
Dissociation of the Inhibitory Apoptosis Stimulating Protein of p53 (iASPP) Binding with Transcription Factor p73 Induces Synovial Fibroblast Apoptosis in the Rheumatoid Joint
Chrong-Reen Wang¹, Shih-Yao Chen¹, Ai-Li Shiau², Ming-Fei Liu¹ and Chao-Liang Wu³, ¹Internal Medicine, National Cheng Kung University Medical College and Hospital, Tainan, Taiwan, ²Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, ³Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan
Background/Purpose: Apoptosis-resistant synovial fibroblasts (SFs) constitute the major cell component of pannus tissues in rheumatoid arthritis (RA). In tumor cells, the binding of inhibitory…
Abstract Number: 458 • 2016 ACR/ARHP Annual Meeting
The TAM Receptors Axl and Mer Play a Protective Role in a Temporal and Spatial Manner in Inflammatory Arthritis
Claire E.J. Waterborg¹, Paqui G. Través², Silke Beermann¹, Marije I. Koenders¹, Greg Lemke² and Fons A.J. van de Loo¹, ¹Experimental Rheumatology, Radboudumc, Nijmegen, Netherlands, ²Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by an unrestrained inflammatory response in selective, anatomically distinct synovial joints. The innate immune system…
Abstract Number: 2581 • 2016 ACR/ARHP Annual Meeting
Tripterygium Wilfordii Hook F Applied Topically in Patients with Active Rheumatoid Arthritis
Juan Jiao¹, Hai-bo Yin², Xiao-po Tang², Xun Gong² and Quan Jiang¹, ¹Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, ²Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
Background/Purpose: Tripterygium wilfordii Hook F (TwHF), a traditional Chinese herb, is widely used in China for treating Rheumatoid Arthritis (RA), but limited only for eldly…
Abstract Number: 544 • 2015 ACR/ARHP Annual Meeting
IL-6 May Have an Important Role in the Resistance to Anti-TNF Therapies of Human T-Lymphotropic Virus Type 1 (HTLV-1) Positive Rheumatoid Arthritis (RA) Patients; HTLV-1 Infected Cells Activate the Inflammatory Responses of RA Synovial Fibroblasts
Kunihiko Umekita¹, Shunichi Miyauchi¹, Kazuyoshi Kubo¹, Kazumi Umeki¹, Hajime Nomura¹, Mao Komura¹, Koushou Iwao¹, Ichiro Takajo¹, Yasuhiro Nagatomo¹, Toshihiko Hidaka² and Akihiko Okayama¹, ¹Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan, ²Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan
Background/Purpose: We reported that human T-lymphotropic virus type 1 (HTLV-1) positive patients with rheumatoid arthritis (RA) had higher inflammation and greater resistance to anti-TNF treatment…
Abstract Number: 2102 • 2015 ACR/ARHP Annual Meeting
Higher Persistence and Adherence with Combination Therapy with Tumor Necrosis Factor Inhibitor+Methotrexate Combination Versus Triple Therapy in US Veterans with Rheumatoid Arthritis
Brian Sauer¹, Chia-Chen Teng², Jianwei Leng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Bradley S. Stolshek⁶, Derek Tang⁶ and Grant W. Cannon⁷, ¹IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Internal Medicine Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA, ⁷Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT

Background/Purpose: Randomized controlled trials in RA have reported efficacy with both triple therapy (methotrexate [MTX] + hydroxychloroquine [HCQ] + sulfasalazine [SSZ]) and tumor necrosis factor…
Abstract Number: 582 • 2015 ACR/ARHP Annual Meeting
Biological Drugs Dose Tapering in Inflammatory Rheumatic Diseases: 2 Year Results at Basurto University Hospital
Juan María Blanco-Madrigal¹, Maria Luz Garcia Vivar¹, Catalina Gomez Arango¹, Olaia Fernández Berrizbeitia¹, Clara Perez Velasquez¹, Ignacio Torre Salaberri², Jose Francisco Garcia Llorente³, Eva Galindez-Agirregoikoa⁴, Esther Ruiz Lucea¹ and Iñigo Gorostiza⁵, ¹Rheumatology, Basurto University Hospital, Bilbao, Spain, ²Rheumaytology, Basurto University Hospital, Bilbao, Spain, ³Rheumatology, Basurto University Hospital., Bilbao, Spain, ⁴Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ⁵Research Department, BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain
Background/Purpose: Last years, biological dose tapering in patients with inflammatory diseases has become a routine clinical practice. Since 2011 we are applying a dose reduction…
Abstract Number: 2546 • 2015 ACR/ARHP Annual Meeting
Targeting Synovial Fibroblasts By the Intra-Articular Delivery of microRNA-140-3p and -5p Ameliorates Experimental Autoimmune Arthritis
Chrong-Reen Wang¹, Jia-Shiou Peng², Shih-Yao Chen³, Chao-Liang Wu⁴ and Ai-Li Shiau⁵, ¹Rheum/Immun Sec/Int Med Dept, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ²Institute of Basic Medical Sciences, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ³Internal Medicine, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ⁴Biochemistry and Molecular Biology, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ⁵Microbiology and Immunology, College of Medicine, National Cheng Kung University, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan
Background/Purpose: Synovial fibroblasts (SF) with aberrant expression of microRNAs (miRNA) are critical pathogenic regulators of rheumatoid joint, and studies examining the effect of overexpressing or…
Abstract Number: 1038 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha and Peptidylarginine Deiminase 4 in Lung and Joint Inflammation
Mandar Bawadekar¹, Annette Gendron-Fitzpatrick², Thomas F. Warner³, Lennart K.A. Lundblad⁴, Paul Thompson⁵ and Miriam A. Shelef^1,6, ¹Medicine, University of Wisconsin, Madison, WI, ²Comparative Pathology Laboratory of the Research Animal Resources Center and Pathobiological Sciences, University of Wisconsin, Madison, WI, ³Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, ⁴Medicine, The University of Vermont, Burlington, VT, ⁵University of Massachusetts, Worcester, MA, ⁶Medicine, William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: The relationship between lung and joint inflammation in rheumatoid arthritis is poorly understood. About 10% of people with rheumatoid arthritis develop interstitial lung disease…
Abstract Number: 2564 • 2015 ACR/ARHP Annual Meeting
Nuclear Receptor 4A2 Is Selectively Upregulated in the Human TNF-Alpha Transgenic Model of Rheumatoid Arthritis
Jackeline Araujo, Cullen Lilley and Kimberlee Mix, Biological Sciences, Loyola University New Orleans, New Orleans, LA
Background/Purpose: The orphan nuclear receptor 4A2 (NR4A2 / NURR1) is emerging as a critical transcription factor in chronic inflammatory joint diseases. We have demonstrated elevated…
Abstract Number: 1039 • 2015 ACR/ARHP Annual Meeting
The Safety and Effect on Disease Activity of Tocilizumab in Combination with MTX Versus Tocilizumab Monotherapy in Patients with Mild to Moderate RA: An Attempt to Optimise the Treatment Response
Burkhard Leeb^1,2, Raimund Lunzer³, Peter Fasching⁴, Manfred Herold⁵, O. Zamani⁶, Winfried Graninger⁷ and OPTIMISE trial Investigators, ¹2nd Dept. of Medicine, State Hospital Stockerau, Center for Rheumatology Lower Austria, Stockerau, Austria, ²Department of Clinical Rheumatology, Karl Landsteiner Society, Stockerau, Austria, ³Department of Internal Medicine, Hospital Barmherzige Brüder Graz-Eggenberg, Graz, Austria, ⁴Department of Internal Medicine V, Wilhelminen Hospital Vienna, Vienna, Austria, ⁵Internal Medicine VI, Medical University of Innsbruck, Austria, Innsbruck, Austria, ⁶Rheumazentrum Favoriten, Wien, Austria, ⁷Rheumatology and Immunology, Medical University of Graz, Graz, Austria
Background/Purpose: An Austrian multi-center study of the effect on disease activity and the safety of Tocilizumab (TCZ) in combination with Methotrexate (MTX) versus TCZ Monotherapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].